bb 21217
Alternative Names: Anti-BCMA CAR T-cell- Genetix Biotherapeutics/Celgene; BB 212172; bb21217Latest Information Update: 03 Oct 2025
At a glance
- Originator bluebird bio
- Developer Genetix Biotherapeutics
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Yes - Multiple myeloma
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Multiple myeloma
Most Recent Events
- 18 Sep 2025 bluebird bio is now called Genetix Biotherapeutics
- 01 Apr 2024 Regeneron Pharmaceuticals acquires anti-cancer immune cell therapies from 2seventy bio
- 11 Jan 2022 Discontinued - Phase-I for Multiple myeloma (Second-line therapy or greater) in USA (Parenteral) due to portfolio prioritization